13F Holdings
中文EN

QDEL QuidelOrtho Corp

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1906324 · Fiscal year ends 01/01

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.5%
TTM net income YoY68.7%
TTM EPS YoY69.0%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—

Margins

Gross margin44.2%
Operating margin-4.9%
Net margin-14.2%
FCF margin-4.5%
EBITDA margin12.9%

Returns

ROE-19.3%
ROA-6.4%
ROIC (approx.)-2.2%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets69.0%
Debt / equity1.64x
Current ratio1.36x
Interest coverage-0.60x

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-28FY20242024-12-29FY20232023-12-31FY20222023-01-01FY20222022-01-02
Income statement
Revenue$2.73B$2.78B$3.00B$3.27B$1.70B
Cost of revenue$1.46B$1.50B$1.50B$1.33B$420.30M
Gross profit$1.27B$1.29B$1.50B$1.94B$1.28B
R&D expense$186.20M$218.70M$245.00M$187.90M$95.70M
SG&A expense$746.30M$766.80M$763.20M$621.00M$239.60M
Operating income-$919.20M-$1.96B$139.10M$843.70M$906.00M
Interest expense$177.60M$163.50M$147.60M$75.70M—
Pretax income-$1.11B-$2.13B-$29.10M$735.90M$900.30M
Income tax$24.10M-$79.50M-$19.00M$187.20M$196.10M
Net income-$1.13B-$2.05B-$10.10M$548.70M$704.20M
EBITDA-$477.20M-$1.51B$596.30M$1.13B$958.70M
EPS (basic)-16.69-30.54-0.159.6616.74
EPS (diluted)-16.69-30.54-0.159.5616.43
Weighted avg. shares (diluted)67.80M67.20M66.80M57.40M42.90M
Banking
Net interest income—-$163.50M-$147.60M-$75.70M-$5.80M
Balance sheet
Cash & equivalents$169.80M$98.50M$119.50M$293.90M$802.80M
Short-term investments—$0$48.40M$52.10M$25.70M
Receivables$417.00M$282.40M$303.30M$453.90M$378.00M
Inventory$577.60M$533.70M$577.80M$524.10M$198.80M
Current assets$1.45B$1.22B$1.31B$1.58B$1.44B
PP&E, net$1.36B$1.38B$1.44B$1.34B$349.20M
Goodwill$0$649.50M$2.49B$2.48B$337.00M
Intangibles$2.56B$2.74B$2.93B$3.12B$98.70M
Total assets$5.77B$6.42B$8.56B$8.86B$2.43B
Current liabilities$966.10M$998.80M$833.80M$1.01B$323.50M
Short-term debt$178.30M$341.80M$139.80M$207.50M$300,000
Long-term debt$2.47B$2.14B$2.27B$2.43B$700,000
Total debt$2.65B$2.48B$2.41B$2.64B$1.00M
Total liabilities$3.85B$3.44B$3.56B$3.92B$501.00M
Shareholders' equity$1.92B$2.98B$5.01B$4.93B$1.93B
Net debt$2.48B$2.38B$2.30B$2.34B-$801.80M
Shares outstanding67.90M67.30M66.70M66.40M41.70M
Cash flow statement
Operating cash flow$105.20M$83.00M$280.20M$885.30M$805.90M
Capital expenditure$188.20M$195.10M$209.30M$140.90M$292.80M
Free cash flow-$83.00M-$112.10M$70.90M$744.40M$513.10M
Investing cash flow-$192.70M-$149.90M-$187.60M-$1.64B-$319.50M
Financing cash flow$155.80M$48.80M-$265.80M$252.00M-$173.10M
Depreciation & amortization$442.00M$453.40M$457.20M$283.60M$52.70M
Stock-based compensation$45.90M$42.10M$51.60M$48.40M$25.40M
Share buybacks$0$0$7.20M$74.30M$103.50M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.